Oncology Venture

OMX: OV.ST

SEK235.4m market cap

SEK1.94 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Investment summary

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. The company’s goal is to then develop is portfolio of drugs that are active within populations that the DRP can identify. The company recently focused its strategy on three lead assets: the TKI dovitinib, the PARP inhibitor 2X-121, and the microtubule inhibitor agent Ixempra.

Y/E Dec
Revenue (DKKm)
EBITDA (DKKm)
PBT (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 5.1 (23.8) (31.0) (127.00) N/A N/A
2018A 2.1 (32.3) (22.5) (44.00) N/A N/A
2019E 3.6 (116.4) (117.0) (165.02) N/A N/A
2020E 3.6 (131.2) (130.3) (170.62) N/A N/A
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Last updated on 04/12/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (DKKm) 81.1
Forecast gearing ratio (%) 80
Price performance
%
1m
3m
12m
Actual (0.3) (45.6) (65.7)
Relative* 0.1 (49.2) (70.2)
52-week high/low SEK7.3/SEK1.8
*% relative to local index
Key management
Duncan Moore Chairman
Steve Carchedi CEO
Henrik Moltke CFO
Ulla Hald Buhl Chief Operating Officer